Direct Healthcare Professional Communication (DHPC) on intravenous tranexamic acid formulations: Serious, including fatal, adverse reactions due to accidental intrathecal administration
2025.12.11
Active substance: tranexamic acid
The marketing authorisation holders would like to inform you that tranexamic acid injectable formulation is authorised for intravenous use only. Intrathecal, epidural, intraventricular and intracerebral use of tranexamic acid injectable is contraindicated. Serious, including fatal, adverse reactions have been reported after inadvertent intrathecal administration due to mix-ups, mostly with injectable local anaesthetics.
Download DHPC/Information letter , Download_VeroeffentlichtAm_EN